Pharmacogenomics of Antihypertensive Drugs

These drugs are commonly used but, in some cases, they may become harmful for the person who is going through this medication so in this case pharmacogenomics of antihypertensive drugs are used. There are a variety of useful medication adherence classes, including anti hypertensive drugs, ACE inhibitors, Betablockers, and calcium channel blockers. Despite multiple effective medication classes and numerous medicines into each class, high blood pressure (BP) management rates are poor. According to estimates, only around thirty-five of hypertensive individuals have both diastolicand systolic blood pressure management (Thoenes M.et. al.,2009), with same counts from United States (Chobanian AV et. al.2003) and other countries (Mori H et. al.2006). This loss of blood pressure management is not due to a lack of medication; according to one research, around thirty percent of medicated hypertensives use one hypertension medicine, forty percent take two fludrocortisone, and thirty percent take three or even more fludrocortisones (Rodriguez-Roca GC et. al. 2009). The findings show that the present trial-and-error methodology to bp therapy is ineffective, and that new methods for determining the best hypertensive strategy for a given individual are required. The genomic data, or functional genomics, application is to determine the best appropriate medicine for specific patient is major way for individualizing hypertension treatment. Considering the high health costs of hypertension and the low rates of blood pressure management, hypertension pharmacodynamics has a lot of promise. Epigenetics is concerned with genes, transcriptomes, and proteins. It have ability to improve patient care by enhancing illness detection and adopting patient-specific therapies. Molecular genetic pharmacogenetics was formerly centered on clinical studies. It is presently being expanded by applying genome-wide techniques to clarify the hereditary basis of variances in medication responsiveness across people.